Search results for "AGENT"

showing 10 items of 8904 documents

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus

2021

BACKGROUND Oral lichen planus (OLP) is a common, frequently symptomatic, immune-mediated disease. Various treatments have been used for symptomatic OLP, including corticosteroids and immunosuppressants administered topically or systemically. The aim of this study was to compare the effectiveness of topical dexamethasone vs. topical cyclosporine in treatment of symptomatic OLP. MATERIAL AND METHODS Thirty-two patients with biopsy-proven symptomatic OLP were randomly assigned to two therapeutic groups: dexamethasone 2mg/5ml or cyclosporine 100mg/ml, both administered topically in a swish and spit method three times a day for 4 weeks. The patients were followed up for a total of 6 months. Asse…

medicine.medical_specialtyTopical dexamethasoneAdministration TopicalGastroenterologyDexamethasonelaw.inventionRandomized controlled triallawInternal medicinemedicine3-d printingHumansGeneral DentistryDexamethasoneUNESCO:CIENCIAS MÉDICASbusiness.industryorthognathic surgerysplintsmedicine.diseaseDysphagiaTreatment periodDiscontinuationClinical trialOtorhinolaryngologydata accuracyCyclosporineSurgeryOral lichen planusmedicine.symptombusinessImmunosuppressive Agentsmedicine.drugLichen Planus Oral
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct

Efficacy of botulinum toxin in the treatment of bruxism : systematic review

2019

Background Currently it has been shown that botulinum toxin is effective for a wide variety of medical conditions, and can be applied for therapeutic purposes as cosmetic. In recent years, there has been a growing trend in the use of this drug substance to control the muscular overactivity of bruxism. The objective of this study was the use of botulinum toxin type A (BTX-A) than traditional methods, by conducting a systematic review of randomized clinical trials (RCTs) published in the health sciences literature. Material and Methods An electronic search was made in the databases of the PubMed, Cochrane Library and Scopus data between March and October 2017, ECA, which will analyze the effe…

medicine.medical_specialtyToxina botulínicaMEDLINEReviewCochrane LibraryPlaceboInjections Intramuscularlaw.inventionMasseter muscleOcclusal Splints03 medical and health sciences0302 clinical medicineRandomized controlled triallawBotulinum toxinmedicineHumansBotulinum Toxins Type AGeneral DentistryOral Medicine and Pathologybusiness.industryMasseter MuscleBruxisme030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Botulinum toxinstomatognathic diseasesOtorhinolaryngologyNeuromuscular AgentsUNESCO::CIENCIAS MÉDICASPhysical therapySurgeryBruxismbusinessBiomedical sciencesmedicine.drug
researchProduct

AISF position paper on HCV in immunocompromised patients.

2018

Abstract This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

medicine.medical_specialtyTransplant RecipientComorbidityAntiviral AgentsOrgan transplantation03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineImmunocompromised patientHumansChronicIntensive care medicineAntiviral AgentHepatologybusiness.industryGastroenterologyHepatologyHepatitis C Chronicmedicine.diseaseComorbidityHepatitis COrgan transplantHCV; Immunocompromised patients; Organ transplant; Hepatology; GastroenterologyTransplant RecipientsHCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised HostItaly030220 oncology & carcinogenesisHCVHCV Immunocompromised patients Organ transplantPosition paperNeoplasmImmunocompromised patients030211 gastroenterology & hepatologyImmunocompetencebusinessImmunocompetenceDirect actingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommenda…

2020

Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large- scale, clinical studies there is considerable variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise treatment approaches the European Society of Blood and Marrow Transplantation published recommendations on the management of GVHD in the setting of HLA-identical sibling or unrelated donor transplantation in adult patients with haematological malignancies. Here we update these recommendations including the results of study published after 2014. Evidence was searc…

medicine.medical_specialtyTransplantation ConditioningDrug ResistanceMEDLINEGraft vs Host DiseaseBronchiolitis obliteransDisease03 medical and health sciences0302 clinical medicinegraft versus host diseasemedicineHumansDisease management (health)Intensive care medicineImmunosuppression Therapybusiness.industryDisease ManagementHematologymedicine.disease3. Good healthAnti-thymocyte globulinTransplantationSystematic reviewGraft-versus-host diseasesurgical procedures operativeHematologic Neoplasms030220 oncology & carcinogenesisDrug MonitoringbusinessImmunosuppressive AgentsStem Cell Transplantation030215 immunology
researchProduct

Early onset of depression and treatment outcome in patients with major depressive disorder

2021

Major depressive disorder (MDD) is a highly heterogeneous disorder, which may partly explain why treatment outcome using antidepressants is unsatisfactory. We investigated the onset of depression as a possible clinical marker for therapy response prediction in the context of somatic biomarkers blood pressure and plasma electrolyte concentration. 889 MDD patients were divided into early (EO, n = 226), intermediate (IO, n = 493), and late onset (LO, n = 169) patients and were analyzed for differences in socio-demographic and clinical parameters, comorbidities and treatment outcome as well as systolic blood pressure and electrolytes. EO patients more often suffered from a recurrent depression,…

medicine.medical_specialtyTreatment outcomeLate onsetContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientAge of OnsetBiological PsychiatryDepression (differential diagnoses)Early onsetDepressive Disorder MajorDepressionbusiness.industrymedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTreatment OutcomeBlood pressureMajor depressive disorderbusiness030217 neurology & neurosurgeryJournal of Psychiatric Research
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct